2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.
ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
… leader who can navigate the complexities of early clinical-stage programs. In this role, the candidate will: … applications eg INDs/CTAs and manage the clinicaltrial approval processes. Ensure that the content, quality, …
He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.
… Senior Clinical Scientist ProQR Therapeutics is a biotechnology … our development organization in preparation to start clinical development of our Axiomer pipeline, as a result we … Excellent knowledge of GCP, clinical operations, clinicaltrials, translation from pre-clinical to phase 1, scientific …
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.